Skip to main content

Advertisement

Springer Nature Link
Log in

A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

In epithelial ovarian cancer (EOC), the cancer antigen 125 (CA-125) has been conventionally used to help in diagnosis and assessment of response to treatment. Currently, YKL-40 (Tyrosine–Lysine–Leucine-40) and circulating cell-free DNA are being evaluated for possession of similar ability. In this study, we aimed to assess the ability of a repertoire of potential biomarkers in detecting and assessing therapeutic response, in advanced EOC. Blood levels of CA-125, YKL-40, total cell-free DNA (CFDNA), cell-free nuclear DNA (CFnDNA), and cell-free mitochondrial DNA (CFmDNA) levels were measured in 100 untreated patients of advanced EOC from November 2009 to June 2011, and again on treatment completion from the 20 patients who appeared for follow-up analysis. Significantly, higher proportion of untreated patients had serum CA-125 >3 times upper limit of normal (ULN) (90.0 %; P < 0.0001) and plasma YKL-40 >ULN (77.0 %; P < 0.0001), both of which significantly decreased, Posttherapy. posttherapy, CFDNA (P < 0.0001), and CFnDNA (P < 0.0001) levels significantly decreased as compared to pretreatment levels. Positive and significant correlations existed between pretherapy CFDNA and CFnDNA [Spearman rho (ρ) = 1.000; P < 0.0001], and also with CFmDNA (ρ = 0.301; P = 0.002), separately between CFnDNA and CFmDNA (ρ = 0.303; P = 0.002), as well as between plasma YKL-40 and patient age (ρ = 0.353; (P < 0.0001). On treatment completion, CFDNA and CFnDNA levels showed positive and significant correlation (ρ = 1.000; P < 0.0001). Therefore serum CA-125 and plasma YKL-40 aid detection and assessment of therapeutic response, in advanced EOC. CFDNA and CFnDNA help in estimating extent of therapeutic response in advanced EOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. GLOBOCAN (IARC) Section of Cancer Information (2008) http://globocan.iarc.fr/. Accessed 8 May 2011

  2. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM, Simpson JL, Sood AK (2006) Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 5:1369–1374

    Article  CAS  PubMed  Google Scholar 

  3. Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Roxana I, Baselga J, Del Campo JM (2008) Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 19:327–331

    Article  CAS  PubMed  Google Scholar 

  4. Bast RC Jr (2004) Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc 115:233–247

    Google Scholar 

  5. Crawford SM, Peace J (2005) Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16:47–50

    Article  CAS  PubMed  Google Scholar 

  6. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS (2006) Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454–1458

    Article  CAS  PubMed  Google Scholar 

  7. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO (2010) Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31:209–215

    Article  CAS  PubMed  Google Scholar 

  8. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, Holland EC, Spriggs DR (2004) Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22:3330–3339

    Article  CAS  PubMed  Google Scholar 

  9. Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Moller L, Price PA, Christensen LH (2009) YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9:8

    Article  PubMed Central  PubMed  Google Scholar 

  10. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28:4456–4468

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D (2009) Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng 28:142–145

    PubMed  Google Scholar 

  12. Dehn H, Hogdall EV, Johansen JS, Jorgensen M, Price PA, Engelholm SA, Hogdall CK (2003) Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 82:287–293

    Article  PubMed  Google Scholar 

  13. Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE (2007) Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 13:421–426

    Article  CAS  PubMed  Google Scholar 

  14. Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635:105–117

    Article  CAS  PubMed  Google Scholar 

  15. Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X (2008) Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol 112:843–850

    Article  CAS  PubMed  Google Scholar 

  16. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK (2010) Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 116:1918–1925

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Ellinger J, Muller SC, Wernert N, von Ruecker A, Bastian PJ (2008) Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int 102:628–632

    Article  PubMed  Google Scholar 

  18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  CAS  PubMed  Google Scholar 

  19. Badgwell D, Bast RC Jr (2007) Early detection of ovarian cancer. Dis Markers 23:397–410

    Article  CAS  PubMed  Google Scholar 

  20. Bouanene H, Harrabi I, Ferchichi S, Ben Limem H, Miled A (2007) Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer. Bull Cancer 94:E18–E22

    PubMed  Google Scholar 

  21. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194–202

    Article  CAS  PubMed  Google Scholar 

  22. Yin BW, Lloyd KO (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371–27375

    Article  CAS  PubMed  Google Scholar 

  23. Karam AK, Karlan BY (2010) Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol 7:335–339

    Article  CAS  PubMed  Google Scholar 

  24. Tuxen MK, Soletormos G, Dombernowsky P (2001) Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 84:1301–1307

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Gupta D, Lammersfeld CA, Vashi PG, Braun DP (2010) Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer. J Ovarian Res 3:22

    Article  PubMed Central  PubMed  Google Scholar 

  26. Rathcke CN, Vestergaard H (2009) YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8:61

    Article  PubMed Central  PubMed  Google Scholar 

  27. Lee CG, Elias JA (2010) Role of breast regression protein-39/YKL-40 in asthma and allergic responses. Allergy Asthma Immunol Res 2:20–27

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Copeland WC, Wachsman JT, Johnson FM, Penta JS (2002) Mitochondrial DNA alterations in cancer. Cancer Invest 20:557–569

    Article  CAS  PubMed  Google Scholar 

  29. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Burki N, Diesch C, Holzgreve W, Zhong XY (2009) Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 8:105

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge all our recruited patients and their families, without whose co-operation this study would have been impossible.

Author information

Authors and Affiliations

  1. Department of Biochemistry, All India Institute of Medical Sciences, Room No. 3027A, New Delhi, 110029, India

    Sharmistha Choudhuri, Chandresh Sharma, Ayan Banerjee & Neeta Singh

  2. Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, 110029, India

    Sunesh Kumar

  3. Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, 110029, India

    Lalit Kumar

Authors
  1. Sharmistha Choudhuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chandresh Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayan Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sunesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lalit Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neeta Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neeta Singh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choudhuri, S., Sharma, C., Banerjee, A. et al. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. Mol Cell Biochem 386, 259–269 (2014). https://doi.org/10.1007/s11010-013-1863-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-013-1863-8

Keywords

Search

Navigation